Merck grabs amped-up flu drug
https://www.profitableratecpm.com/f4ffsdxe?key=39b1ebce72f3758345b2155c98e6709c
Merck is paying $9.2 billion for Cidara Therapeutics and its Phase 3 antiviral drug designed to prevent infection with influenza A and B in people at high risk of complications.
In the United States, an estimated 560,000 to 1.1 million people were hospitalized with the flu during the 2024-2025 season, according to data from the Centers for Disease Control and Prevention.
